These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33134181)

  • 21. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of pretreatment neutrophil count in metastatic renal cell carcinoma: a systematic review and meta-analysis.
    Shen J; Chen Z; Fan M; Lu H; Zhuang Q; He X
    Cancer Manag Res; 2019; 11():5365-5374. PubMed ID: 31354345
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma.
    Kara O; Maurice MJ; Zargar H; Malkoc E; Akca O; Andrade HS; Ramirez D; Caputo PA; Nelson RJ; Rini B; Kaouk JH
    Int Urol Nephrol; 2016 Aug; 48(8):1253-1260. PubMed ID: 27215555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically.
    Yang B; Xia H; Xu C; Lu M; Zhang S; Wang G; Ma L
    BMC Urol; 2020 Feb; 20(1):14. PubMed ID: 32070319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
    J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; Santoni M; de Cobelli O; Nolé F
    Crit Rev Oncol Hematol; 2016 Mar; 99():324-31. PubMed ID: 26818051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2018 May; 480():166-172. PubMed ID: 29462592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and meta-analysis of clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with tumor thrombus treated by radical nephrectomy with thrombectomy.
    Gu L; Li H; Wang Z; Wang B; Huang Q; Lyu X; Shen D; Gao Y; Fan Y; Li X; Xie Y; Du S; Liu K; Tang L; Peng C; Ma X; Zhang X
    Cancer Treat Rev; 2018 Sep; 69():112-120. PubMed ID: 29960124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
    Kim SH; Lee DE; Joung JY; Seo HK; Lee KH; Chung J
    Investig Clin Urol; 2020 Mar; 61(2):146-157. PubMed ID: 32158965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Zhou X; Fu G; Zu X; Xu Z; Li HT; D'souza A; Tulpule V; Quinn DI; Bhowmick NA; Weisenberger DJ; Liang G; Chen J
    Urol Oncol; 2022 Jan; 40(1):12.e13-12.e22. PubMed ID: 34454823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis.
    Takemura K; Yonekura S; Downey LE; Evangelopoulos D; Heng DYC
    Eur Urol Open Sci; 2022 May; 39():62-71. PubMed ID: 35528786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Hsieh PY; Hung SC; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Cheng CL; Chiu KY
    Urol Oncol; 2021 Jul; 39(7):422-430. PubMed ID: 33934963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
    Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
    Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Deng H; Liu W; He T; Hong Z; Yi F; Wei Y; Zhang W
    Front Oncol; 2019; 9():479. PubMed ID: 31293962
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.